Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis

Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)

(2011) Chris M. Kozma et al.   CURRENT MEDICAL RESEARCH AND OPINION

Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America

(2011) Rogelio Apiquian et al.   Neuropsychiatric Disease and Treatment

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

(2011) Larry Alphs et al.   Annals of General Psychiatry

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium

(2011) Tim Lambert et al.   Annals of General Psychiatry

Predictors of switching antipsychotic medications in the treatment of schizophrenia

(2010) Allen W Nyhuis et al.   BMC Psychiatry

Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective

(2010) Deborah Nicholl et al.   CURRENT MEDICAL RESEARCH AND OPINION

Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration

(2010) X. S. Ren et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

(2009) Douglas E Faries et al.   BMC Psychiatry

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)

(2009) J.M. Olivares et al.   EUROPEAN PSYCHIATRY

Relapse and Long-Acting Injectable Risperidone: A 1-Year Mirror Image Study with a National Claims Database in Taiwan

(2009) Kuan-Pin Su et al.   VALUE IN HEALTH

Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System

(2009) M. Fuller et al.   JOURNAL OF MEDICAL ECONOMICS

Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia

(2008) Gunnar Morken et al.   BMC Psychiatry

Impact of risperidone long acting injection on resource utilization in psychiatric secondary care

(2008) M. Taylor et al.   JOURNAL OF PSYCHOPHARMACOLOGY